Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites

Abstract

Objective: The purpose of this study is to compare the difference of clinical efficacy between conventional intraperitoneal chemotherapy and HIPEC, so as to explore the clinical application value and advantages of HIPEC. Design: A retrospective analysis was conducted on 80 patients with malignant ascites admitted to our hospital from June 2017 to June 2019. The general clinical data and qualitative data of the treatment results of 80 patients with malignant ascites were processed by SPSS19.0 using χ 2 test, and quantitative data were processed by t test. P < 0.05, statistical data can be considered statistically significant. Results: 1. There was no significant change in vital signs and temperature in the observation group during the treatment, and the difference was not statistically significant. 2. The short-term total effective rate of patients in the observation group was 91.11%, and the short-term total effective rate of the patients in the control group was 40%. 3. There was no significant difference in the incidence of adverse reactions between the two groups of patients. Conclusion: Intraperitoneal hyperthermic chemotherapy combined with intravenous chemotherapy can significantly control malignant ascites and has small adverse reactions, which is worthy of clinical promotion and application.

Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis

“…The results suggested that HIPEC had a significant advantage in controlling malignant ascites in those patients. A study showed that HIPEC combined with systemic chemotherapy also achieve ascites control, with few adverse events [ 40 ]. In addition, except for two side effects associated with oxaliplatin, i.e., neutropenia and neurotoxicity, HIPEC did not significantly increase the incidence of adverse events within 30 days after the operation.…”

Docetaxel HIPEC Combined with Endostar versus Docetaxel HIPEC Alone in Treatment of Malignant Ascites：A Retrospective Study

“…First the infusion uid can mechanically remove abdominal isolated cancer cells. Then during the process, chemotherapeutic drugs are infused into the abdominal cavity, so as to form a circumstance of high and durable concentration in the peritoneal cavity [12]. There is a natural peritonealplasma barrier (PPB) in our body,which limits the resorption of drugs from the peritoneal cavity into the blood [13].…”

Laparoscopic Heated Intraperitoneal Chemotherapy in the Treatment of Carcinomatosis of Gastric Adenocarcinoma Origin

“…Although no randomized trials exist to study the use of LS-HIPEC in the treatment of malignant ascites, it has been favorably reported in several series, offering an option to palliate this difficult problem [ 20 , 21 , 22 ]. These studies demonstrate that a significant reduction in ascites can be achieved in 91–94% of patients in reported series [ 22 , 23 ]. While rates of significant complications (Grade 3 or 4) are low, even in these medically frail patients, ranging from 2 to 12% [ 22 , 24 ].…”